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S U M M A R Y
Background: Enterobacteriaceae bacteremia is a common complication in patients with neoplasm. The
cancer itself, chemotherapy-induced immunosuppression, and other cancer-related procedures play a
role as predisposing factors for this condition. However, despite the clear association between cancer and
Enterobacteriaceae bacteremia, the distinctive clinical characteristics of patients with cancer presenting
with Enterobacteriaceae bacteremia have not been well established.
Methods: The population studied was a prospective cohort of adult hospitalized patients with
Enterobacteriaceae bacteremia in a tertiary care hospital. We compared the clinical variables and
microbiological features between patients with an underlying neoplasm (n = 203) and those without
(n = 259). STATA software was used for statistical association analysis.
Results: In a bivariate analysis, older age, prior exposure to aminopenicillins, fewer days of symptoms,
biliary source of bacteremia, greater severity of APACHE II score, lower white blood cell and platelet
counts, and the presence of Klebsiella pneumoniae were more common in the neoplasm group. In a
multivariable analysis, K. pneumoniae bacteremia (odds ratio (OR) 6.13, 95% conﬁdence interval (CI)
1.65–22.71; p = 0.007), APACHE II score (OR 1.18, 95% CI 1.05–1.34; p = 0.007), and exposure to
aminopenicillins (OR 28.84, 95% CI 1.94–429.3; p = 0.015) were associated with neoplasm. K. pneumoniae
bacteremia was more commonly present in patients with lung and gastrointestinal cancers.
Conclusions: We have conﬁrmed the association of K. pneumoniae bacteremia with underlying neoplastic
disease, especially with gastrointestinal malignancies, which may allow stratiﬁcation for initial empiric
antibiotic therapy in this subset of patients. Prior exposure to aminopenicillins in the neoplasm group
might contribute to this ﬁnding.
Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Sepsis is one of the leading causes of morbidity and mortality in
the USA.1 The proportion of sepsis caused by Gram-negative bacilli
(Enterobacteriaceae) is epidemiologically signiﬁcant, and carries an
overall increase in mortality.2,3 Sepsis itself is a spectrum that
spans presentation of localized infection with transient bacteremia
and rapid recovery to multi-organ failure and death. The
population affected by this condition is heterogeneous due to
different demographic factors, causative organisms, infection
sources, host genetic diversity, etc. Importantly, host predisposi-
tion factors play a role in the acquisition of bacteremia and the
development of sepsis; among these are age, underlying medical
illness, immunosuppression, and breach of integrity of the natural* Corresponding author.
E-mail address: andres.henaomartinez@ucdenver.edu (A.F. Henao-Martı´nez).
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http://dx.doi.org/10.1016/j.ijid.2012.11.030host barriers. Neoplasm is a common ﬁnding in this setting as one
of the predisposing factors, and it has been postulated that the
relative risk of sepsis is almost 10 times greater in patients with
cancer compared to the general population.4 Chemotherapy-
induced neutropenia and mucositis, long-term catheter place-
ments, and immune system dysfunction are among the neoplasm-
related conditions that place those patients at greater risk of
developing bacteremia and sepsis.5
Due to this great heterogeneity in the patient population and
the dramatic variety in outcomes, it is important to establish
clinical strategies to identify patients at greater risk for worse
outcomes or with underlying undiagnosed risk factors, to provide
more speciﬁc evaluation and therapy. The possible distinctive
clinical characteristics of Gram-negative sepsis in this subgroup of
patients that would allow for a better risk stratiﬁcation have not
yet been fully established. The aim of this study was to identify
clinical characterizing factors of the subset of patients with
Enterobacteriaceae bacteremia and an underlying neoplasm.nal Society for Infectious Diseases.
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2.1. Patients and data collection
We performed a database analysis of a prospective cohort study
in a tertiary care hospital that included adult hospitalized patients
with Enterobacteriaceae sepsis and bacteremia. The study partici-
pants consisted of subjects selected from the Sepsis Registry at the
Duke University Medical Center, Durham, North Carolina. The data
collection took place from 2002 to 2007. Inclusion criteria for the
study were deﬁned as adults (18 years) with culture-conﬁrmed
Enterobacteriaceae bacteremia. Exclusion criteria were negative
blood cultures, outpatient status, and isolation of any pathogen
other than Enterobacteriaceae from blood culture. The study
collected clinical variable data and microbiological features among
468 patients. We performed a statistical analysis of clinical
variables in patients with neoplasm vs. those without; clinical
variables included demographics (age, sex, and gender), risk
factors (presence or absence of diabetes mellitus, use of corticoste-
roids at presentation, surgery in the previous 30 days, transplanted
organ recipient status, exposure to antibiotics over the last 30 days,
exposure to aminopenicillins over the same period of time, and
hemodialysis), symptoms (presence or absence of fever, tempera-
ture 38 8C, and days of symptoms before presentation), route of
acquisition (community vs. healthcare associated), main known
sources of bacteremia (urinary, biliary, pneumonia, or indwelling
intravascular catheter-related bacteremia), laboratory data (white
blood cell (WBC) count, platelet count, and serum creatinine and
albumin), sepsis severity score (APACHE II), complications
(presence or absence of organ injury (kidney or lung), septic
shock, disseminated intravascular coagulation (DIC), mechanical
ventilation, or all-cause attributable mortality), total days of
effective antibiotic therapy, and the microbiology characteristics
(type of Enterobacteriaceae in the blood culture and presence of
polymicrobial bacteremia).
Blood cultures were processed using the BACTEC 9240
automated culturing system. Antibiotic exposure was deﬁned as
any antibiotic therapy >24 h but <30 days prior to the time when
the positive blood cultures were drawn. Neoplasm included any
type of cancer: hematologic or solid organ. Aminopenicillin
exposure was deﬁned as previous treatment with amoxicillin or
ampicillin. Indwelling intravascular catheter included any periph-
eral, central, peripherally inserted, tunneled, or arterial intravas-
cular catheters. Infection of a catheter line was deﬁned as having
simultaneous positive blood cultures from the line and from a
peripheral site, with ﬁrst positivity arising from the line.
Polymicrobial bacteremia was considered as the presence of more
than one Enterobacteriaceae or one Enterobacteriaceae and another
different organism. Total days of effective antibiotic therapy was
deﬁned as the time an effective antibiotic was started based on
antibiogram susceptibility results of the isolate to the time at
which therapy was completed.
2.2. Statistical analysis
We performed an initial bivariate analysis and compared the
categorical variables using Chi-square tests. Analyses were
performed excluding missing values. We determined whether
our continuous variables followed a normal distribution using the
Shapiro–Wilk test. We used the t-test to compare these variables
between patients with and without neoplasm. We included all
variables whose tests for association with neoplasm rendered a p-
value of 0.25 in a forward, stepwise, multivariate logistic
regression model. A two-sided p-value of <0.05 was considered
to indicate a statistically signiﬁcant difference. All analyses were
performed using STATA software.3. Results
3.1. Clinical characteristics of the Enterobacteriaceae bacteremia
cohort
A total of 468 patients with Enterobacteriaceae bacteremia
were analyzed. The mean age was 56.9  16.3 years; 255
patients were male (54.5%), 312 were Caucasian (66.7%), and 132
(28.2%) were African-American. Fever was present in 410 of 456
(89.9%) of the patients. We identiﬁed a total of 169 (37.0%)
healthcare-associated bacteremias and 288 (63.0%) community-
acquired bacteremias in 457 observations. From the analyzed
cohort, 189 of 453 (41.7%) patients had previously received
antibiotic therapy and 155 of 456 (34.0%) had undergone a
surgical procedure over the last 30 days before presentation.
Regarding co-morbidities, 130 of 463 (28.1%) patients had a
diagnosis of diabetes mellitus, 57 of 461 (12.4%) were transplant
recipients, and 52 of 461 (11.3%) had received hemodialysis. Of
436 patients, the three most common known sources of
bacteremia were genitourinary with 111 patients (25.5%),
catheter-related  blood stream infection (CRBSI) with 73
(16.7%), and biliary tract with 23 (5.3%). Laboratory data were
(mean  standard deviation): WBC count 10.7  8.5  109/l,
platelet count 175.3  126.7  109/l, albumin 2.8  0.8 mg/dl,
and creatinine 2.02  2.39 mg/dl. The most common bacterial
species isolated among 461 patients were Escherichia coli with
146 (31.7%) and Klebsiella pneumoniae with 99 (21.5%). The mean
APACHE II score was 13.42  5.92, with a portion of 305 patients
developing septic shock (90; 29.5%), acute lung injury (39; 12.8%),
acute kidney injury (30; 9.8%), DIC (21; 6.9%), and death (10.2%;
47 of 459).
3.2. Clinical characteristics of the subset of patients with neoplasia
compared to those without neoplasia
A total of six patients were excluded because of missing data
regarding neoplasm status. Of the 462, we identiﬁed 203 patients
with a diagnosis of neoplasm. Of patients with neoplasm, the mean
age was 59.6  15.3 years; 120 (59.1%) patients were male, 158
(77.8%) were Caucasian, and 39 (19.2%) were African-American. The
most common species isolated in this group was K. pneumoniae (62/
201, 30.8%). Compared to patients without neoplasm (Table 1),
patients with neoplasm were older (59.6  15.3 vs. 54.8  16.9;
p = 0.002), had a smaller proportion of African-American subjects
(19.2% vs. 35.3%; p = 0.0001), had fewer days of symptoms
(3.15  4.45 vs. 4.77  9.62; p = 0.03), had more healthcare-associat-
ed infections (42.5% vs. 32.3%; p = 0.03), and greater exposure to
aminopenicillins (10.5% vs. 2.1%; p = 0.018). A biliary source of
infection was more common among patients with underlying
neoplasia (8.2% vs. 3.2%; p = 0.03). Conversely, CRBSI (12.0% vs.
20.2%; p = 0.02) and urinary source (16.3% vs. 32.4%; p = 0.0001) were
less common in this population. Diabetes mellitus (17.2% vs. 36.7%;
p = 0.0001) and previous transplantation (5.4% vs. 17.4%; p = 0.0001)
were also less common in this group. The APACHE II score was higher
in this group (14.3  5.2 vs. 12.7  6.4; p = 0.004), in contrast to WBC
count (10.7  8.6 vs. 11.7  7.8; p = 0.005), platelet count
(174.6  127.1 vs. 196.6  119.5; p = 0.0001), and serum creatinine
(1.4  1.3 vs. 2.5  2.9; p = 0.0001). The serum creatinine discrepancy
is explained in part due to the lower proportion of patients in this
group receiving hemodialysis (4 (2.0%) vs. 48 (18.7%); p = 0.0001).
In a multivariate analysis (Table 2), K. pneumoniae bacteremia
(odds ratio (OR) 6.13, 95% conﬁdence interval (CI) 1.65–22.71;
p = 0.007), APACHE II score (OR 1.18, 95% CI 1.05–1.34;
p = 0.007), and previous exposure to aminopenicillins (OR
28.84, 95% CI 1.94–429.3; p = 0.015) were associated with
underlying neoplasm.
Table 1
Comparison of patients with and without neoplasm (N = 462)
Variables N Neoplasm p-Values
No (n = 259) Yes (n = 203)
Age 462 54.8  16.9 59.6  15.3 0.002a
Race 461 n = 258 n = 203 0.0001a
Caucasian 150 (58.1%) 158 (77.8%)
African-American 91 (35.3%) 39 (19.2%)
Gender, male 462 133/259 (51.4%) 120/203 (59.1%) 0.1
Fever 453 224/252 (88.9%) 183/201 (91.0%) 0.45
Days of symptoms, mean  SD 444 4.77  9.62 3.15  4.45 0.03a
Route 451 n = 251 n = 200
Healthcare 81 (32.3%) 85 (42.5%) 0.03a
Community-acquired 170 (67.7%) 115 (57.5%) 0.03a
Antibiotic exposure in the last 30 days 452 105/254 (41.3%) 83/198 (41.9%) 0.90
Exposure to aminopenicillins 173 2/97 (2.1%) 8/76 (10.5%) 0.018a
Source 431 n = 247 n = 184
Urinary 80 (32.4%) 30 (16.3%) 0.0001a
CRBSI 50 (20.2%) 22 (12.0%) 0.02a
Biliary 8 (3.2%) 15 (8.2%) 0.03a
Pneumonia 10 (4.1%) 8 (4.4%) 0.88
Other/unknown 99 (40.1%) 109 (59.2%)
Surgery in last 30 days 450 79/250 (31.6%) 74/200 (37.0%) 0.23
Diabetes mellitus 462 95/259 (36.7%) 35/203 (17.2%) 0.0001a
Transplant recipient 460 45/258 (17.4%) 11/202 (5.4%) 0.0001a
Corticosteroids 459 65/256 (25.4%) 40/203 (19.7%) 0.15
Septic shock 300 49/178 (27.5%) 37/122 (30.3%) 0.6
APACHE II score, mean  SD 462 12.7  6.4 14.3  5.2 0.004a
WBC count,  109/l, mean  SD 459 11.7  7.8 10.7  8.6 0.005a
Platelet count,  109/l, mean  SD 457 196.6  119.5 174.6  127.1 0.0001a
Albumin, mean  SD 203 2.8  0.9 2.8  0.8 0.77
Creatinine, mean  SD 456 2.5  2.9 1.4  1.3 0.0001a
Bacteremia
Escherichia coli 455 88/254 (34.6%) 56/201 (27.9%) 0.12
Klebsiella pneumoniae 455 36/254 (14.2%) 62/201 (30.8%) 0.0001a
Polymicrobial bacteremia 410 36/235 (15.3%) 32/175 (18.3%) 0.42
Enterobacteriaceae + Pseudomonas aeruginosa 462 10/259 (3.9%) 9/203 (4.4%) 0.76
Days of effective antibiotic therapy 397 17.4  12.5 15.8  9.8 0.16
Acute lung injury 300 22/178 (12.4%) 16/122 (13.1%) 0.84
Disseminated intravascular coagulation 300 12/178 (6.7%) 9/122 (7.4%) 0.83
Mechanical ventilation 446 23/251 (9.2%) 14/195 (7.2%) 0.45
Hemodialysis 460 48/257 (18.7%) 4/203 (2.0%) 0.0001a
Death (all causes) 453 28/252 (11.1%) 18/201 (9.0%) 0.45
CRBSI, catheter-related blood stream infection; SD, standard deviation; WBC, white blood cell.
a p-Values < 0.05.
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Patients who developed K. pneumoniae bacteremia (n = 98) had
a greater proportion of underlying neoplasm when compared to
357 individuals who had bacteremia caused by other Enterobac-
teriaceae (62 (63.3%) vs. 139 (38.9%); p = 0.0001). Previous
antibiotic exposure over the last 30 days (38 (39.6%) vs. 150
(42.7%); p = 0.57) and healthcare acquisition (38 (38.4%) vs. 129
(36.8%); p = 0.77) of the bacteremia were not statistically different.
According to the type of underlying neoplasm (Table 3), K.Table 2
Multivariable analysis results for variables associated with neoplasm
Variables OR 95% CI p-Value
Klebsiella pneumoniae 6.13 1.65–22.71 0.007
APACHE II 1.18 1.05–1.34 0.007
Diabetes mellitus 0.19 0.06–0.65 0.008
Aminopenicillin 28.84 1.94–429.3 0.015
Days of symptoms 0.87 0.75–1.01 0.06
Age 1.02 0.99–1.06 0.171
WBC count 0.93 0.87–1.00 0.048
Community-acquired 2.69 0.90–7.99 0.075
Transplant recipient 0.25 0.04–1.55 0.137
CI, conﬁdence interval; OR, odds ratio; WBC, white blood cell.pneumoniae was most frequently observed in patients with lung
(3/7; 42.9%) and gastrointestinal cancers (24/57; 42.1%), followed
by genitourinary (8/22; 36.4%) and hematologic malignancies (22/
76; 28.9%).
4. Discussion
We found that the subgroup of patients with neoplasm
presenting with Enterobacteriaceae bacteremia were moreTable 3
Distribution of Klebsiella pneumoniae bacteremia cases per cancer type




Lung 7 3 (42.9%)
Gastrointestinal 57 24 (42.1%)
Genitourinary 22 8 (36.4%)
Hematologic 76 22 (28.9%)
Gynecologic 10 1 (10%)
Breast 11 0 (0%)
Central nervous system 2 0 (0%)
Other 16 4 (25%)
Total 201 62
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be explained in part due to host and pathogen associated
factors. Previous reports have identiﬁed underlying malignan-
cy of between 14% and 34% among patients with K. pneumoniae
bacteremia and up to 53% in K. pneumoniae nosocomial
bacteremia.6–9 In our cohort, this number was signiﬁcantly
higher (63%), which could be explained in part by the higher
proportion of healthcare-associated cases identiﬁed. Other
bacteremias such as those caused by Pseudomonas aeruginosa,
Enterobacter spp, and Streptococcus bovis have also been
associated with malignancies,10,11 most commonly of gastro-
intestinal origin.
Pathogen-related factors, such as different capsular, pili,
lipopolysaccharide (LPS), and siderophore determinants,12 may
confer an adaptive advantage in patients with underlying
malignancy and increase the potential for gastrointestinal
translocation or bioﬁlm formation in indwelling intravascular
catheters, thus resulting in K. pneumoniae bacteremia over other
intestinal commensals or colonizers. These are some of the
potential explanations for the association we observed in our
cohort. K. pneumoniae has been described colonizing the
oropharynx among ill hospitalized patients and the gastrointes-
tinal tract in long-term care facility residents.13,14 Moreover, the
nosocomial acquisition of K. pneumoniae bacteremia in cancer
patients has been linked to higher mortality and to previous
antibiotic exposure and antibiotic resistance.9,15,16 In our cohort,
healthcare-associated bacteremia was more frequently observed
in patients with neoplasm; interestingly neither healthcare-
related nor previous antibiotic exposure over the last 30 days
were associated with K. pneumoniae bacteremia. Those risk factors
may be more important in resistance antibiotic selection rather
than invasiveness capabilities.
Exposure to aminopenicillins in the group of patients with
neoplasm was signiﬁcantly different to that of those without
cancer; this may contribute to the selection of K. pneumoniae in
this population. It is known that the presence of a chromosomal
gene encoding a penicillin-speciﬁc beta-lactamase confers K.
pneumoniae resistance to ampicillin.17 In contrast, albeit with
some geographic variation, human isolates of E. coli in the USA
have a 16.5% rate of resistance to ampicillin.18 Despite
controlling for this type of exposure, there was still an
association of K. pneumoniae bacteremia in patients with
underlying malignancy, suggesting that there may be a role
for other intrinsic potential virulent factors. However, other
associated factors conferring a potential advantage for invasive-
ness in this setting are not known.
Host-related factors may also vary depending on the type of
underlying malignancy, since demographics, the degree of
gastrointestinal mucositis, chemotherapy-induced neutropenia,
surgical interventions, and long-term devices may differ signiﬁ-
cantly among the different malignancies. Some other possible
variations in outcomes may also be associated with the different
antibiotic susceptibility of the bacteria, device colonization
capabilities, and selection related to the particular procedures
for each type of cancer.
It is important to note that there are some limitations to the
ﬁndings drawn from this study. The clinical characteristics
delineated from patients with cancer in our study may not apply
to other cohorts with different underlying co-morbidities. This
cohort included only bacteremia due to Enterobacteriaceae,
which excluded important healthcare-related Gram-negative
pathogens such as Pseudomonas and Acinetobacter. We were
also unable to control for other potential important variables,
including among others, the type of chemotherapy, degree of
mucositis, and time since device placement, which may have
confounded the ﬁndings. This study conﬁrms that the subgroupsof patients with cancer are more prone to develop K. pneumoniae
bacteremia due to their intrinsic demographic and epidemio-
logical characteristics.
In conclusion, sepsis and bacteremia are dynamic processes
with great diversity and heterogeneity in different patient
populations. In the subpopulation of patients with underlying
malignancy there may be a speciﬁc predisposition for Enterobac-
teriaceae bacteremia to be caused by K. pneumoniae. This may allow
the targeting of initial empiric antibiotic therapy based on local
institutional antibiotic susceptibility patterns.
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